BC Week In Review | Sep 22, 2017
Clinical News

Novartis starts Phase IIb of KAF156 for malaria

Novartis AG (NYSE:NVS; SIX:NOVN) and Medicines for Malaria Venture (Geneva, Switzerland) began a Phase IIb trial of KAF156 plus a "new, improved formulation" of the antimalarial lumefantrine to treat malaria. The single-blind, African and Asian...
BC Innovations | Sep 29, 2016
Targets & Mechanisms

Hitting for the cycle

Driven by the need for antimalarial drugs that hit all stages of the life cycle of the malaria parasite, a group at the Broad Institute of MIT and Harvard has constructed and screened a diverse...
BC Innovations | Oct 22, 2015
Distillery Therapeutics

Therapeutics: An undetermined target

Infectious disease INDICATION: Malaria Mouse and cell studies identified an artemisinin analog that could help treat malaria. Chemical synthesis and in vitro testing of nitric oxide (NO)-donating dihydroartemisinin analogs identified a compound that inhibited growth...
BC Week In Review | Apr 14, 2014
Company News

Novartis, Malaria No More infectious news

The partners are providing 2 million treatments of a pediatric formulation of Novartis' malaria drug Coartem artemether/lumefantrine - called Coartem Dispersible - to Zambia through Malaria No More's Power of One Campaign. The non-profit is providing 1...
BC Week In Review | Apr 7, 2014
Clinical News

Artemether: Preliminary Phase III data

Preliminary data from the modified intent-to-treat (mITT) population of 141 children with severe or complicated Plasmodium falciparum malaria or uncomplicated P. falciparum malaria with gastrointestinal complications in the open-label, African ART004 Phase III trial showed...
BC Innovations | Dec 19, 2013
Targets & Mechanisms

Lipid kinase enters the malaria stage

A Novartis AG - University of California, San Diego -led consortium has identified a new class of antimalarials that, unlike marketed drugs, eliminates Plasmodium at all stages of its infection cycle. 1 The pharma is developing...
BC Week In Review | May 6, 2013
Company News

Novartis, Malaria No More infectious news

Novartis will provide undisclosed financial support and donate up to 3 million courses of a pediatric formulation of malaria drug Coartem artemether/lumefantrine - called Coartem Dispersible - over the next three years to charity Malaria No More's...
BC Innovations | Apr 25, 2013
Distillery Techniques

Technology: Chemistry

Approach Summary Licensing status Publication and contact information Chemistry Semisynthetic synthesis of artemisinin Biological production of artemisinic acid and chemical conversion of the acid to artemisinin could help supply first-line treatments for malaria infection at...
BC Week In Review | Dec 24, 2012
Clinical News

Kaletra lopinavir/ritonavir: Phase III data

Researchers at the University of California , San Francisco, and colleagues reported data from the open-label, Ugandan Phase III PROMOTE-PEDS trial in 176 HIV-infected children ages 2 months to 5 years showing that Kaletra plus 2...
BC Extra | Sep 13, 2012
Politics & Policy

FDA lowers fee to use Priority Review voucher

FDA set the fee for companies to use a Priority Review voucher at $3.6 million for FY13, down from $5.3 million in FY12. The fee is adjusted each fiscal year to account for the difference...
Items per page:
1 - 10 of 47